As shown in Figures 3(a) and 3(b), patients without APC mutations did not have prolonged overall survival from TCGA CRC cohort (HR 1.00 (95% CI 0.64–1.56), P > 0.05) and MSKCC pancancer immunotherapy cohort (HR 1.13 (95% CI 0.88–1.45), P > 0.05). This evidence concerns the gene APC and colorectal carcinoma.